Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment-Reference-Cited by-同舟云学术

Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment

Published:2016-10 Issue:2 Volume:380 Page:494-504
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Shi Puyu,Oh You-Take,Zhang Guojing,Yao Weilong,Yue Ping,Li Yikun,Kanteti Rajani,Riehm Jacob,Salgia Ravi,Owonikoko Taofeek K.,Ramalingam Suresh S.,Chen Mingwei,Sun Shi-Yong

Funder

NIH/NCI

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference26 articles.

1. Cancer statistics, 2015;Siegel;CA Cancer J. Clin,2015

2. Global cancer statistics, 2012;Torre;CA Cancer J. Clin,2015

3. Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance;Tartarone;Ther. Adv. Respir. Dis,2015

4. Fighting cancer drug resistance: opportunities and challenges for mutation-specific EGFR inhibitors;Juchum;Drug Resist. Updat,2015

5. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins;Remon;Cancer Treat. Rev,2014

Cited by 140 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis and biological evaluation of novel quinazoline-derived EGFR/HER-2 dual-target inhibitors bearing a heterocyclic-containing tail as potential anti-tumor agents;Bioorganic Chemistry;2024-10

2. Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts;Cancer Research Communications;2024-09-01

3. Case report: A case of Savolitinib in the treatment of MET amplification mutation advanced lung adenocarcinoma with rare bilateral breast metastasis;Frontiers in Oncology;2024-08-13

4. A new 1,2,3-triazole-indirubin hybrid suppresses tumor growth and pulmonary metastasis by mitigating the HGF/c-MET axis in hepatocellular carcinoma;Journal of Advanced Research;2024-08

5. Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges;Frontiers in Immunology;2024-04-09